On Monday 26 September, the European Commission announced the purchase of 10,000 treatments of the antiviral drug Tecovirimat (see EUROPE B13001A10) to be used against monkeypox.
The procurement was carried out by the new Health Emergency Preparedness and Response Authority (HERA) through a joint procurement procedure.
Using a different set of logistics than those for the delivery of HERA-secured monkeypox vaccines (see EUROPE B12971A4), Tecovirimat treatments will be delivered through the...